943322-87-0

Usage

Uses

Used in Chemical Research:
N-[(2S)-2-AMINO-2-PHENYLETHYL]-CARBAMIC ACID 1,1-DIMETHYLETHYL ESTER is used as a research tool for studying the dopamine biosynthetic pathway, providing insights into the mechanisms of neurotransmitter production and regulation.
Used in Drug Development:
In the pharmaceutical industry, N-[(2S)-2-AMINO-2-PHENYLETHYL]-CARBAMIC ACID 1,1-DIMETHYLETHYL ESTER may have potential applications in the development of drugs targeting the dopaminergic system, which could be beneficial for treating neurological disorders associated with dopamine imbalances, such as Parkinson's disease and schizophrenia.
Used in Medicinal Chemistry:
N-[(2S)-2-AMINO-2-PHENYLETHYL]-CARBAMIC ACID 1,1-DIMETHYLETHYL ESTER is utilized in medicinal chemistry for the synthesis of novel compounds with potential therapeutic effects. Its unique structure and properties make it a valuable starting material for the design and synthesis of new drugs targeting the dopaminergic system.
Used in Neuropharmacology:
In the field of neuropharmacology, N-[(2S)-2-AMINO-2-PHENYLETHYL]-CARBAMIC ACID 1,1-DIMETHYLETHYL ESTER serves as a valuable compound for investigating the role of dopamine in various neurological processes and disorders. Its use in research can contribute to a better understanding of the mechanisms underlying dopamine-related conditions and aid in the development of more effective treatments.

InChI:InChI=1S/C13H20N2O2/c1-13(2,3)17-12(16)15-9-11(14)10-7-5-4-6-8-10/h4-8,11H,9,14H2,1-3H3,(H,15,16)/t11-/m1/s1

Upstream product

• 1374635-42-3 tert-butyl N-[(2S)-2-(benzyloxycarbonylamino)-2-phenyl-ethyl]carbamate 
• 117049-14-6 tert-butyl N-[(1S)-2-hydroxy-1-phenylethyl]carbamate 
• 2900-27-8 (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid 
• 130406-36-9 ((S)-2-Amino-1-phenyl-ethyl)-carbamic acid benzyl ester 
• 190393-65-8 (S)-2-<(benzyloxycarbonyl)amino>-2-phenyl ethyl azide 
• 144125-06-4 (S)-2-azido-1-phenyl-ethylamine 
• 110143-62-9 (S)-(+)-<2-<(methylsulfonyl)oxy>-1-phenylethyl>carbamic acid 1,1-dimethylethyl ester 
• 137102-29-5 (S)-(+)-1-<(butoxycarbonyl)amino>-1-phenylethyl azide 
• 1374635-44-5 tert-butyl N-[(2S)-2-(benzyloxycarbonylamino)-3,3-dimethyl-butyl]carbamate 
• 86013-50-5 (R)-(2-hydroxy-2-phenyl-ethyl)carbamic acid tert-butyl ester 
• 2549-14-6 (R)-2-Amino-1-phenylethanol 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1390672-82-8 C₂₈H₂₉N₃O₃*ClH 
• 1390672-83-9 (S)-di-tert-butyl 2-{3-[(S)-2-((S)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)pyrrolidine-2-carboxamido)-2-phenylethyl]thioureido}succinate 
• 1390672-84-0 (S)-di-tert-butyl 2-{3-[(S)-2-phenyl-2-[(S)-pyrrolidine-2-carboxamido]ethyl]thioureido}succinate 
• 1390672-81-7 (S)-(9H-fluoren-9-yl)methyl 2-[(S)-2-(tert-butoxycarbonylamino)-1-phenylethylcarbamoyl]pyrrolididne-1-carboxylate 
• 1403934-70-2 (S)-N-diphenylphosphinyl-phenylethane-1,2-diamine 
• 1386981-09-4 ((S)-2-{4-chloro-3-[(2-methoxy-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonyl)-amino]-benzoylamino}-2-phenyl-ethyl)-carbamic acid tert-butyl ester 
• 1386980-12-6 (S)-N-(5-(2-amino-1-phenylethylcarbamoyl)-2-chlorophenyl)-2-methoxy-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamide 

Relevant academic research and scientific papers

COMBINATIONS AND DOSING REGIMES TO TREAT RB-POSITIVE TUMORS

This invention directed to methods for treating select RB-positive cancers and other Rb- positive abnormal cellular proliferative disorders using CDK4/6 inhibitors in specific dosing and combination or alternation regimes. In one aspect, treatments of select RB-positive cancers are disclosed using specific CDK4/6 inhibitors in combination or alternation with another chemotherapeutic, for example, an additional kinase inhibitor, PD-1 inhibitor, or BCL-2 inhibitor, or combination thereof.

CDK INHIBITORS

Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.

A tripeptide-like prolinamide-thiourea as an aldol reaction catalyst

A tripeptide-like prolinamide-thiourea catalyst with (S)-proline, (1S,2S)-diphenylethylenediamine and (S)-di-tert-butyl aspartate as building blocks provides the products of the reaction between ketones and aromatic aldehydes in high to quantitative yields and high stereoselectivities (up to 99:1 dr and 99% ee). Both the chiral centers of the diamine unit are essential, while the thiourea hydrogen originating from the amine and the amide hydrogen play a predominant role for the catalyst efficiency.

PYRIDO PYRIMIDINES

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.

CARBOXYLIC ACID ARYL AMIDES

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer.